Acrux Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARUXF research report →
About the company
Acrux Limited, alongside its affiliated entities, specializes in the global development and commercialization of generic and topical pharmaceutical products. The company's reach extends across international markets, including Australia, Europe, and the United States. A significant part of its offerings includes diverse testosterone therapies, available in various forms such as oral and buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels, all aimed at treating adult men with low or absent testosterone levels.
- CEO
- John Warmbrunn
- IPO
- 2010
- Employees
- 43
- HQ
- West Melbourne, VIC, AU
Price Chart
- Market Cap
- $6.78M
- P/E
- -2.09
- P/S
- 1.71
- P/B
- 4.11
- EV/EBITDA
- -1.62
- Div Yield
- 0.00%
- Gross Margin
- 56.94%
- Op Margin
- -185.41%
- Net Margin
- -83.81%
- ROE
- -211.88%
- ROIC
- -120.27%
- Revenue
- $1.19M · -76.63%
- Net Income
- $-5,945,000 · -2.50%
- EPS
- $-0.02 · 15.50%
- Op Income
- $-8,972,000
- FCF YoY
- -19.59%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.99
- Avg Volume
- 1.79K
Get TickerSpark's AI analysis on ARUXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ARUXF coverage
Recent articles, reports, and earnings notes.
No research on ARUXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARUXF report →Similar companies
Peers in the same neighborhood.